Recent Finacing
Recent Raise
ImCheck Therapeutics develops antibodies targeting the butyrophilin superfamily for immune modulation, advancing γδ T‑cell‑activating ICT01 in Phase I/IIa and preclinical activating and antagonist programs for oncology, autoimmune, infectious diseases.
